Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.

The difference in the primary endpoint (LMR) between the lubiprostone and control groups was only marginally statistically significant (p value = 0.049), and we did not apply any multiple comparison methods.

also in 1,110 other papers